HDAC9 and mesenchymal chondrosarcoma: Moreover, we showed that sensitivity to romidepsin is independent of the IDH mutation status and the chondrosarcoma subtype (i.e., central conventional-, dedifferentiated-, or mesenchymal chondrosarcoma), indicating that HDAC inhibition could be a promising therapeutic strategy for all chondrosarcoma patients.